Rare Ventures Launches: A $25 Million Venture Philanthropy Platform to Accelerate Rare Disease Therapies
Key Insights
The Richard King Mellon Foundation (search) has committed up to $25 million to launch Rare Ventures, a first-of-its-kind venture philanthropy platform for accelerating rare disease therapies.
The initiative unites Carnegie Mellon University, the University of Pittsburgh, UPMC, Stanford Medicine, ElevateBio (search), and the EB Research Partnership (search) to combine AI, clinical research, and therapeutic development.
More than 400 million people worldwide live with a rare disease, yet approximately 95% of the 10,000+ rare diseases lack an approved treatment.
The Richard King Mellon Foundation (search) has committed up to $25 million to launch Rare Ventures, a first-of-its-kind venture philanthropy platform designed to accelerate the development of therapies for rare diseases and to create a new model for medical innovation. The Pittsburgh-based partnership brings together leaders in medicine, biotechnology, and artificial intelligence, uniting the EB Research Partnership (search) (EBRP) with Carnegie Mellon University, the University of Pittsburgh Health Sciences, UPMC Children's Hospital of Pittsburgh, UPMC Vision Institute, Stanford Medicine, and ElevateBio (search).
The scale of the unmet need is substantial. More than 400 million people worldwide live with a rare disease, yet about 95% of the 10,000+ rare diseases do not have an approved treatment. While scientific advances in genomics, gene editing, AI, and biotechnology have transformed what is possible in medicine, turning discoveries into approved therapies remains a slow and difficult process, especially for rare diseases. Rare Ventures aims to close that gap by combining AI, clinical research, therapeutic development, manufacturing, and commercialization to create a faster, more coordinated path to treatments and cures.
"By bringing together artificial intelligence, venture philanthropy, therapeutic development and world-class institutions, we are building a new model designed to accelerate therapies and create hope for millions of families around the world," said Michael Hund, CEO of EBRP and co-founder of Rare Ventures.
Carnegie Mellon's Role as Technology Core
As the technology core of Rare Ventures, Carnegie Mellon researchers will work across every stage of the therapeutic process, helping accelerate the path from scientific discovery to patient impact. This spans understanding the biological cause of a disease, identifying the right therapeutic target, designing a promising therapy, and delivering it to the right cells in the body.
"The convergence of artificial intelligence, automated chemistry, computational biology, genomics and medicine is creating entirely new possibilities for understanding and treating human disease," said Barbara Shinn-Cunningham, Glen de Vries Dean of CMU's Mellon College of Science. "Rare Ventures represents an exciting opportunity to bring together expertise across disciplines to tackle some of the most difficult challenges in healthcare."
University infrastructure such as the AI Science Foundry and the new Richard King Mellon Hall of Sciences will bring together researchers in life sciences and AI. These efforts will also inform the Helix Foundry, which will use automated chemistry to synthesize libraries of nucleic acid molecules for testing as potential therapeutics.
CMU researchers are already applying automation and AI to accelerate scientific discovery through several approaches, including developing a deep learning method called KGWAS that improves detection of genetic variants and associated traits for rare diseases; using AI to computationally screen thousands of possible chemical structures to identify potential drug candidates; studying pyruvate dehydrogenase complex (PDC) disease to develop molecules that restore normal protein function; and working on diverse methods for delivering therapeutic nucleic acids to specific tissues and cells.
"If you want to push the frontiers of medicine, you need to do it through computational and experimental innovations. As the technology core, we're positioned to address immediate clinical needs, improve existing technologies and spark new innovations that could dramatically expand the number of diseases that can be treated," said Bruce Armitage, professor and head of the Department of Chemistry and co-director of the Center for Nucleic Acids Science and Technology.
A Venture Philanthropy Model Built on EB Success
Rare Ventures builds upon EBRP's model that has demonstrated success with epidermolysis bullosa (search) (EB), a rare genetic condition that causes fragile, blistering skin. Individuals with EB lack critical proteins that bind the skin's two layers together; without these proteins, the skin tears apart, blisters, and shears off, leading to severe pain, disfigurement, and internal and external wounds that may never heal.
Over the past 14 years, EBRP has helped fund more than 180 research projects in 22 countries, contributed to the expansion of the EB clinical trial landscape from two active trials to more than 50, and accelerated the development of three FDA-approved therapies in the last three years. Through its venture philanthropy approach, EBRP has demonstrated that financial returns generated from successful therapies can be reinvested into future research, creating a sustainable cycle of innovation and impact.
Rare Ventures expands that model beyond a single disease. In addition to epidermolysis bullosa (search), partners at UPMC have identified six additional rare diseases that will be a focus of the initiative over the next three years.
"Throughout our work with the EB community, we've seen what can happen when patients, researchers, physicians, philanthropists and industry leaders unite around a common purpose," said Jill and Eddie Vedder, co-founders of EBRP. "Rare Ventures represents the next chapter of that journey. We're taking lessons learned from one disease and building something that can help families facing thousands of rare diseases. Every patient deserves hope, and every breakthrough deserves the chance to reach the people who need it most."
Pittsburgh as the Home of Rare Ventures
Pittsburgh was chosen as the home of Rare Ventures because of its unique concentration of strengths across AI, life sciences, clinical research, advanced manufacturing, and translational medicine.
"Rare diseases represent one of the greatest unmet challenges in medicine, affecting millions of families while receiving only a fraction of the attention and resources devoted to more common conditions," said Sam Reiman, director and trustee of the Richard King Mellon Foundation (search). "Rare Ventures brings together an exceptional group of partners around a bold vision: creating the infrastructure, partnerships and innovation ecosystem needed to accelerate therapies for patients. We believe Pittsburgh possesses the talent, institutions and collaborative spirit necessary to lead this effort, and we are proud to support its launch."
Rare Ventures is designed to grow into a platform capable of supporting hundreds of disease communities over time. It aims to create a self-sustaining model in which philanthropic capital, venture philanthropy returns, industry partnerships, and platform-based infrastructure continuously generate resources that can be reinvested into future therapeutic development. The long-term vision is to create a scalable engine capable of accelerating therapies across hundreds of rare diseases and serving as a blueprint for the future of medical innovation.
"Ultimately, our success will not be measured by the model we build, the capital we deploy, or the partnerships we unite," Hund said. "It will be measured by the therapies we help bring to patients and the lives we help change. That is the mission that unites everyone behind Rare Ventures and we thank the Richard King Mellon Foundation (search) for making it possible."